Financial Comparison: SurModics (SRDX) & Its Competitors
SurModics (NASDAQ: SRDX) is one of 79 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its competitors? We will compare SurModics to related businesses based on the strength of its analyst recommendations, valuation, dividends, earnings, risk, profitability and institutional ownership.
Volatility & Risk
SurModics has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, SurModics’ competitors have a beta of 0.94, indicating that their average stock price is 6% less volatile than the S&P 500.
This table compares SurModics and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|SurModics||$73.11 million||$3.92 million||99.14|
|SurModics Competitors||$975.11 million||$120.37 million||230.49|
SurModics’ competitors have higher revenue and earnings than SurModics. SurModics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
85.6% of SurModics shares are owned by institutional investors. Comparatively, 65.7% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 6.4% of SurModics shares are owned by insiders. Comparatively, 12.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This table compares SurModics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and recommmendations for SurModics and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
SurModics currently has a consensus target price of $40.00, indicating a potential upside of 39.13%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 7.83%. Given SurModics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe SurModics is more favorable than its competitors.
SurModics beats its competitors on 7 of the 13 factors compared.
SurModics Company Profile
Surmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company’s In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings.
Receive News & Ratings for SurModics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SurModics and related companies with MarketBeat.com's FREE daily email newsletter.